Gefticip 250mg Tablet

Gefticip 250mg Tablet contains Gefitinib, a selective tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). This medication is primarily indicated for the treatment of non-small cell lung cancer (NSCLC). By blocking the action of EGFR, Gefitinib disrupts cancer cell proliferation, making it an essential part of targeted cancer therapy.

Key Features:

• Contains Gefitinib, a potent targeted therapy medication
• Primarily used for treating non-small cell lung cancer (NSCLC)
• Inhibits EGFR activity to slow down the growth of cancer cells
• Convenient oral dosage form for ease of use
• Often prescribed as part of a comprehensive cancer treatment plan